|
|
 |
2017³â ´ëÇÑÀüÇØÁúÇÐȸ Ãá°è Çмú´ëȸ |
ÀÏ ½Ã |
2017³â 6¿ù 24ÀÏ ¿ÀÈÄ 1 ½Ã30ºÐ - 5½Ã 30ºÐ |
Àå ¼Ò |
Àü³²´ëÇб³ Àǰú´ëÇÐ ´öÀçȦ |
Program |
|
Session I Hot topics of Hypertension |
ÁÂÀå: ÀÌÅ¿ø(°æÈñ´ë), ÀÓõ±Ô(°æÈñ´ë) |
1:30-2:00 |
Çѱ¹Çü °íÇ÷¾Ð Áø·á Áöħ |
À̼ҿµ(Â÷ÀǰúÇдë) |
2:00-2:30 |
Hypertension and Kidney : Criminal or Victim |
±è¼¼Áß(¼¿ï´ë) |
2:30-3:00 |
Hypertension in CKD : Beyond the guidelines |
ÀÌ»óÈ£(°æÈñ´ë) |
3:00-3:20 |
Panel discussion: |
¹èÀºÈñ (Àü³²´ë),
·ùµ¿¿(ÀÌÈ¿©´ë),
Á¤°æÈ¯(°æÈñ´ë),
¸¶¼º±Ç(Àü³²´ë) |
3:20-3:30 |
Coffee Break |
|
Session II Hypertension in the real world |
ÁÂÀå: ±è±ÙÈ£(ÇѾç´ë),
±è¼ö¿Ï(Àü³²´ë) |
3:30-4:00 |
Elderly hypertension: Target BP and Drug of Choice |
ÃÖÈ«»ó(Àü³²´ë) |
4:00-4:30 |
Class effect with Anti-hypertensive medications : Clinical considerations |
°°æÇ¥(ÀüºÏ´ë) |
4:30-5:00 |
Control of BP for CKD in the real world: Case review |
¹ÚÁ¾ÇÏ(¿ï»ê´ë) |
5:00-5:20 |
Panel discussion: |
±è¼º±Õ(ÇѸ²´ë),
¹®ÁÖ¿µ(°æÈñ´ë),
ÃÖ´ëÀº(Ãæ³²´ë),
±è⼺(Àü³²´ë) |
5:20-5:30 |
Closing |
|
|
2015³â ´ëÇÑÀüÇØÁúÇÐȸ Ãß°è Çмú´ëȸ |
ÀÏ ½Ã |
2015³â 11¿ù 22ÀÏ (ÀÏ) 09:00 ~ 16:00 |
Àå ¼Ò |
°æÈñ´ëÇб³ Á¾ÇÕ°Àǵ¿(û¿î°ü) ÁöÇÏ1Ãþ ´ë°´ç |
Program |
Á¦ 13ȸ °æÈñ ½ÅÀå ¿¬¼ö°Á |
|
I. Omics Research in Kidney Disease |
ÁÂÀå: ±è±¤Ç¥(°æÈñ´ë), ÀÓõ±Ô(°æÈñ´ë) |
09:00-09:30 |
Genomics:GWAS in IgA nephropathy |
Á¤°æÈ¯(°æÈñ´ë) |
09:30-10:00 |
Transcriptomics in kidney disease |
ÀÌ»óÈ£(°æÈñ´ë) |
10:00-10:30 |
Proteomic research in glomerular disease and transplantation |
±èÂù´ö(°æºÏ´ë) |
10:30-10:50 |
Coffee Break |
|
|
II. Old and New in Glomerular Disease |
ÁÂÀå:±è¿µÈÆ(ÀÎÁ¦´ë),
ÀÌÅ¿ø(°æÈñ´ë) |
10:50-11:20 |
»ç±¸Ã¼ Áúȯ ÀÓ»ó Áø´ÜÀÇ Tips |
ÀÓõ±Ô(°æÈñ´ë) |
11:20-11:50 |
New discovery of etiology:Role of Infection and autoimmunity |
±è¾ç±Õ(°æÈñ´ë) |
11:50-12:20 |
Emerging therapeutic modality:From steroid to new biologic agent |
±è¼¼¿¬(°æÈñ´ë) |
15:00-15:20 |
Coffee Break |
|
´ëÇÑÀüÇØÁúÇÐȸ Ãß°è Çмú´ëȸ |
|
Á¦1ºÎ Interesting Topic |
ÁÂÀå: Çϼº±Ô(¿¬¼¼´ë), ÀÌÁ¾Àº(Àü³²´ë) |
13:30-14:00 |
¸¸¼º»ç±¸Ã¼½Å¿°ÀÇ °íÇ÷¾Ð:º´Àΰú Ä¡·á |
ÀÓõ±Ô(°æÈñ´ë) |
14:00-14:30 |
½ÅÁõÈıº ȯÀÚÀÇ ÀÌ´¢Á¦ Ä¡·á |
±è⼺(Àü³²´ë) |
14:30-15:00 |
Salt sensitivity-Endothelial dysfunction |
ÃÖÈÆ¿µ(¿¬¼¼´ë) |
15:00-15:20 |
Coffee Break |
|
|
Á¦2ºÎ Interesting Case |
ÁÂÀå:±ÇÅÂȯ(°æºÏ´ë), ±è¼ö¿Ï(Àü³²´ë) |
15:20-15:40 |
Familial renal hypouricemia with acute kidney injury |
±èÁø¼÷(°æÈñ´ë) |
15:40-16:00 |
Chronic hypokalemia and nephrocalcinosis |
ÀÌ¿ë±Ô(±¹¹Î °Ç°º¸Çè Àϻ꺴¿ø |
16:00 |
closing Remark |
|
|
2013 Á¦7ȸ ´ëÇÑÇ÷¾×Åõ¼®¿©°ú¿¬±¸È¸ ½ÉÆ÷Áö¾ö |
ÀÏ ½Ã |
2013³â 7¿ù 28ÀÏ (ÀÏ) 08:00 ~ 15:30 |
Àå ¼Ò |
°Ç±¹´ëÇб³º´¿ø ´ë°´ç |
Program |
Online Hemodilafiltration: A to Z |
08:00-08:50 |
Registration |
08:50-09:00 |
Opening Remarks - ´ëÇÑÇ÷¾×Åõ¼®¿©°ú¿¬±¸È¸ ȸÀå ÇÏ ¼º ±Ô |
|
Ãà »ç - °Ç±¹´ëÇб³ ÀÇ·á¿øÀå ¾ç Á¤ Çö |
I. Technical Aspects of Online-HDF - ÁÂÀå:ÀÌÈ£¿µ.À±¿µ¼® |
09:00-09:30 |
Basic Equipments and Principles of Online-HDF - ÇѾçÀÇ´ë ÀÌ Ã¢ È |
09:30-10:00 |
Water Treatment in Online-HDF:Microbiological Quality - Àϻ꺴¿ø ½Å¼®±Õ |
10:00-10:30 |
Anticoagulation in Online-HDF - °Ç±¹ÀÇ´ë Á¶¿µÀÏ |
10:30-10:50 |
COFFEE Break |
II. Clinical Aspects of Online-HDF (1) - ÁÂÀå:ÀÌÅ¿ø.±èÇöö |
10:50-11:20 |
Nutrition in Onlinep-HDF - ÀÎÇÏÀÇ´ë À̽¿ì |
11:20-11:50 |
Substitional Fluid of Online-HDF:Pre-dilution vs. Post-dilution - ÀÎÁ¦ÀÇ´ë ±è¾ç¿í |
11:50-12:20 |
Standard Prescription of Online-HDF - Àü³²ÀÇ´ë ±è⼺ |
12:20-13:20 |
Lunch |
III. Clinical Aspects of Online-HDF (2) - ÁÂÀå:Çϼº±Ô.À̼ºÁÖ |
13:20-13:50 |
Clinical Benefits, Including QOL and Long-term Mortality, of Online-HDF - ¿ï»êÀÇ´ë ÀåÀç¿ø |
13:50-14:20 |
Which Patients Could Benefit from Online-HDF?:Learanig from Cases |
14:20-14:50 |
New Modality of Online-HDF |
14:50-15:20 |
Futures of Online-HDF and Renal Replacement Therapy |
15:20-15:30 |
Closing Remarks |
|
2011 ´ëÇÑÀüÇØÁúÇÐȸ Ãß°èÇмú´ëȸ |
ÀÏ ½Ã |
2011³â 10¿ù 8ÀÏ (Åä) |
Àå ¼Ò |
Á¦ÁÖ ¼±ÍÆ÷ ÄÁº¥¼Ç¼¾ÅÍ |
 |
´ëÇÑÀüÇØÁúÇÐȸ(±èÈ£Áß, ±è±ÙÈ£) |
13:00 - 13:20 |
Renal ammonia metabolism: acidosis vs. chronic hypokalemia - ÀÌÈ¿©ÀÚÀÇ´ë ÇØºÎÇÐ Çѱâȯ |
13:20 - 13:40 |
Dietary sodium in take in chronic kidney disease - ÇѾçÀÇ´ë ³»°ú ±è±ÙÈ£ |
13:40 - 14:00 |
ACE2 and angiotensin 1 -7 in hypertensive renal disease - °æÈñÀÇ´ë ³»°ú ¹®ÁÖ¿µ |
14:00 - 14:20 |
V2 receptor antagonist - ÇѾçÀÇ´ë ³»°ú ÀÌÁÖÇÐ |
|
2010 ´ëÇÑÀüÇØÁúÇÐȸ Ãß°èÇмú´ëȸ |
ÀÏ ½Ã |
2010³â 10¿ù 9ÀÏ (Åä) |
Àå ¼Ò |
´ë±¸ EXCO |
 |
´ëÇÑÀüÇØÁúÇÐȸ(±èÈ£Áß, ±è±ÙÈ£) |
13:00 - 13:30 |
ICU¿¡¼ ÈçÈ÷ Á¢ÇÏ´Â ÀüÇØÁú ÀÌ»ó°ú Ä¡·á¿¡ °üÇÑ ÃÖ½ÅÁö°ß - Áß¾ÓÀÇ´ë ³»°ú ÀÌÀç¿í |
13:30 - 14:00 |
Emerging role of Akt substrate protein AS169 in the regulation of AQP2 translocation (´ëÇÑÀüÇØÁúÇÐȸ ¿¬±¸ºñ °á°ú ¹ßÇ¥) - °æºÏÀÇ´ë »ý¸®ÇÐ ±ÇÅÂȯ |
14:00 - 14:30 |
ICU¿¡¼ ÈçÈ÷ Á¢ÇÏ´Â »ê-¿°±â ÀÌ»ó°ú Ä¡·á¿¡ °úÇÑ ÃÖ½ÅÁö°ß - ¼¿ïÀÇ´ë ³»°ú ¿ÀÀ±±Ô |
|
2010 Á¦ 8ȸ(2010³â, ´ëÇÑÀüÇØÁú ÇÐȸ)Á¤±âÇмú´ëȸ
(APCN SEOUL°ú °°ÀÌ)
|
ÀÏ ½Ã |
2010³â 6¿ù 7ÀÏ (¿ù) |
Àå ¼Ò |
COEX Convention Center |
|
2009 ´ëÇÑÀüÇØÁúÇÐȸ Ãß°èÇмú´ëȸ |
ÀÏ ½Ã |
2009³â 10¿ù 17ÀÏ (Åä) |
Àå ¼Ò |
ÀüºÏ (¹«ÁÖ¸®Á¶Æ® Ƽ·ÑÈ£ÅÚ) |
|
|
|
1. Free Communication |
|
Oral rehydration therapy for acute diarrheal disease - °æÈñÀÇ´ë ±è¼ºµµ |
|
2. Symposium |
|
¸¸¼º ¿ïÇ÷¼º ½ÉºÎÀü¿¡¼ ¼öºÐ ÀüÇØÁú Àå¾Ö ¹× ½Å±â´É ÀÌ»ó - Àü³²ÀÇ´ë ¸¶¼º±Ç |
|
¸¸¼º °£Áúȯ¿¡¼ ¼öºÐ ÀüÇØÁú Àå¾Ö ¹× ½Å±â´É ÀÌ»ó - Áß¾ÓÀÇ´ë ÀÌÀç¿í |
|
±Þ ¸¸¼º ³úÁúȯ¿¡¼ ¼öºÐ ÀüÇØÁú Àå¾Ö ¹× ½Å±â´É ÀÌ»ó - ¼¿ïÀÇ´ë ±èµ¿±â |
|
2009 Á¦ 7ȸ Á¤±âÇмú´ëȸ
|
ÀÏ ½Ã |
2009³â 5¿ù 9ÀÏ (Åä), ¿ÀÈÄ 1½Ã |
Àå ¼Ò |
ÇѾç´ëÇб³ °è´Ü°Àǵ¿ ¼¼¹Ì³ª½Ç |
|
|
13:30-14:00 |
1. Free communication |
14:00-14:30 |
Ubiquitination of renal aquaporin-2 - ±ÇÅÂȯ °æºÏÀÇ´ë |
14:30-15:00 |
Expression of the ammonia transporter family members,
Rh B glycoprotein and Rh C glycoprotein, in the kidney - Çѱâȯ ÀÌÈÀÇ´ë |
15:00-15:30 |
Bedside Approach to acid-base disturbance :
Is newer approach better ?
- ÀÌ¿µ¼÷ À»ÁöÀÇ´ë |
15:30-16:00 |
Coffee Break |
16:00-16:30 |
Renal handling of Ammonium and acid - base regulation - ±èÇý¿µ ÃæºÏÀÇ´ë |
16:30-17:00 |
Acquired Gitelman's syndrome - ±è¿ë±Õ °¡Å縯ÀÇ´ë ¼º°¡º´¿ø |
17:00-17:30 |
Role of pendrin in acid-base regulation - ±è¼¼Áß °¡ÃµÀÇ¿ø |
|
2008 Ãß°è Çмú´ëȸ Çà»ç¾È³» |
ÀÏ ½Ã |
2008³â 10¿ù 18ÀÏ (Åä), ¿ÀÈÄ 1:00-2:30 |
Àå ¼Ò |
´ëÀü ÄÁº¥¼Ç¼¾ÅÍ (´ëÇѽÅÀåÇÐȸ Ãß°èÇмú´ëȸ ±â°£ ³») |
|
|
13:00~13:30 |
1. Free Communications |
|
2. Symposium : Divalent Ions and Kidney |
13:30~13:50 |
Calcium metabolism --POSTECH ÀüÀº½Ç |
13:50~14:10 |
Magnesium metabolism --ÇѸ²ÀÇ´ë ¼Àå¿ø |
14:10-14:30 |
Phosphate metabolism --°Ç¾çÀÇ´ë ÃÖ³«¿ø |
|
2008 Á¦6ȸ Á¤±âÇмú´ëȸ |
ÀÏ ½Ã |
2008³â 3¿ù 15ÀÏ |
Àå ¼Ò |
|
|
|
|
Rosiglitazone prevents impaired renal function and dysregulation of sodium transporters in DOCA-Salt hypertensive (DSH) rats - Àü³²ÀÇ´ë ¹èÀºÈñ |
|
Renal AQP2, ENaC, and NHE3 in rats with experimentally induced heart failure is reversed by angiotensin II type 1 receptor antagonism - Sophie C. |
|
Renin-antiogensin system-considerations for hypertension and kidney - °í´ëÀÇ´ë ÀÓÇüÀº À¯±âȯ |
|
Vasopressin and vasopressin receptor antagonists - ¼¿ïÀÇ´ë ¿ÀÀ±±Ô |
|
Nitric oxide in the kidney: Its physiological role and pathophysiological implications - Àü³²ÀÇ´ë »ý¸®ÇÐ ÀÌÁ¾Àº |
|
Renal effects of Prostaglandins and cyclooxygenase-2 inhibitors - ÇѾçÀÇ´ë ±è±ÙÈ£ |
|
The role of aniopoietin-1 in kidney disease - ÀüºÏÀÇ´ë ±è¿ø |
|
2007 Á¦5ȸ Á¤±âÇмú´ëȸ |
ÀÏ ½Ã |
2007³â 3¿ù 31ÀÏ (Åä) |
Àå ¼Ò |
ÇѾç´ëÇб³º´¿ø °è´Ü°Àǵ¿ 401È£ ¼¼¹Ì³ª½Ç |
|
|
|
Free Communication |
|
Ç×ÀÌ´¢ È£¸£¸ó°ú ¾ÈÁö¿ÀÅٽŠII°¡ ÁýÇÕ°ü »óÇǼ¼Æ÷¿¡¼ ¼öºÐÅë·ÎÀÇ ¼¼Æ÷³» ¼ö¿¡ ¹ÌÄ¡´Â »óÈ£ÀÛ¿ë - °æºÏÀÇ´ë ±ÇÅÂȯ |
|
Regulation of urea transporter by the TonEBP - Ãæ³²ÀÇ´ë Á¤ÁÖ¿µ |
|
±Þ¼º ½ÅºÎÀü ½ÅÀå¿¡¼ antioxidantÀÇ È¿°ú - Àü³²ÀÇ´ë ¹èÀºÈñ |
|
Clinical Science Symposium |
|
´ë»ç¼º »êÁõÀ» µ¿¹ÝÇÑ ³»¿ø ȯÀÚ¿Í Ç÷¾×Åõ¼® ȯÀÚ¿¡¼ Albumin/Lactate Corrected Anion Gap°ú Strong lon Gap(SIG)ÀÇ ÀÓ»óÀû ÀÇ¹Ì¿Í Àû¿ë - À»ÁöÀÇ´ë ÀÌ¿µ¼÷ |
|
Normotensive hypokalemic disorders - ¼¿ïÀÇ´ë ÇÑÁø¼® |
|
Hypertensive hypokalemic disorders - ÀÌÈÀÇ´ë ÃÖ±Ôº¹ |
|
2006 ´ëÇÑÀüÇØÁúÇÐȸ Ãß°èÇмú´ëȸ |
ÀÏ ½Ã |
2006³â 10¿ù 14ÀÏ (Åä) |
Àå ¼Ò |
°æÁÖ Çö´ëÈ£ÅÚ (´ëÇѽÅÀåÇÐȸ Ãß°èÇмú´ëȸ ±â°£ ³») |
|
|
|
Free Communication |
|
Primary aldosteronism in a patient with ESRD
ÀÎÁ¦ÀÇ´ë ¼¿ï¹éº´¿ø ³»°ú ³ªÇöÈñ |
|
Mannitol-induced metabolic alkalosis
ÀüºÏÀÇ´ë ³»°ú °°æÇ¥ |
|
Clinical Symposium : Dysnatremia |
|
Hyponatremia: management errors - ÇѸ²ÀÇ´ë ³»°ú ¼Àå¿ø |
|
Pseudohyponatremia: Does it matter in current clinical practice? - ÇѾç´ë³»°ú ±è±ÙÈ£ |
|
Hypernatremia: Successful Treatment - Àü³²ÀÇ´ë ³»°ú ±è¼ö¿Ï |
|
2006 Á¦ 4ȸ Á¤±âÇмú´ëȸ |
ÀÏ ½Ã |
2006³â 3¿ù 25ÀÏ(Åä), ¿ÀÈÄ 1½Ã |
Àå ¼Ò |
°¡Å縯ÀǰúÇבּ¸¿ø 1002È£ |
|
|
Program |
|
Free Communication |
|
Electrolyte & Blood Pressure topics |
Symposium |
|
1. NO synthesis in the kidney - ÀÌÈÀÇ´ë ÇØºÎÇб³½Ç Çѱâȯ |
|
2. Introduction of organic anion transporters and an regulatory mechanism by
caveolins - ÀÎÇÏÀÇ´ë ¾à¸®ÇÐ Â÷¼®È£ |
|
3. Urea transporters in the kidney - °¡Å縯ÀÇ´ë ¼Ò¾Æ°ú ±èµ¿¾ð |
|
4. Dysregulation of ENaC in animal models of NS & LC - Àü³²ÀÇ´ë ³»°ú ±è¼ö¿Ï |
|
5. The role of angiotensin ll in renal interstitial injury - ÀÎÁ¦ÀÇ´ë ¼Ò¾Æ°ú ±¸ÀÚ¿í |
|
ÅðÀÓ Æ¯º°°¿¬: ÀüºÏÀÇ´ë ³»°ú °¼º±Í |
|
The kidney knows the answers to the hidden message in the water |
|
2005³â Ãß°èÇмú´ëȸ |
ÁÖ Á¦ |
Potassium homeostasis |
ÀÏ ½Ã |
2005³â 10¿ù 8ÀÏ(Åä), ¿ÀÈÄ 2½Ã 10ºÐ - 3½Ã 30ºÐ |
Àå ¼Ò |
Á¦ÁÖ ¶ó¸¶´ÙÇöóÀÚÈ£ÅÚ ÇѶóȦ |
|
|
Program |
|
1. Dietary potassium intake in Korean population -
ÇѾç´ë »ýȰ°úÇдëÇÐ ½Äǰ¿µ¾çÇаú ¾ö¾Ö¼± |
|
2. Regulation of potassium excretion in the kidney -
Àü³²ÀÇ´ë »ý¸®Çб³½Ç ÀÌÁ¾Àº |
|
3. Physiology & pathophysiology of transcellular shift of potassium balance -
¼¿ïÀÇ´ë ³»°ú ³ª±â¿µ |
|
4. Hyperkalemia in chronic renal failure -
ÇѾçÀÇ´ë ³»°ú ÇÑ»ó¿õ |
|
2005³â Á¦ 3ȸ Á¤±âÇмú´ëȸ |
ÁÖ Á¦ |
Potassium homeostasis |
ÀÏ ½Ã |
2005³â 3¿ù 5ÀÏ(Åä), ¿ÀÈÄ 12½Ã 30ºÐ |
Àå ¼Ò |
°¡Å縯´ëÇб³ ÀǰúÇבּ¸¿ø, 1002È£½Ç |
|
|
Program |
1:30-2:00 |
Free communications |
|
Electrolyte & Blood Pressure topics |
2:30-4:00 |
Symposium I |
|
Studies of sodium transporters using cell culture models Àü³²¼öÀÇ´ë ÇÑÈ£Àç |
|
K/O mouse models in salt retention and hypertension °í½ÅÀÇ´ë ¾ÈµµÈ¯ |
|
Adrenomedullin and the kidney ÀüºÏÀÇ´ë ±è ¿ø |
4:30-6:00 |
Symposium II |
|
Renal sodium handling and hypertension ÀÎÁ¦ÀÇ´ë ±è¾ç¿í |
|
Dietary salt and potassium intake and hypertension °¡Å縯ÀÇ´ë À̽ÂÇå |
|
Dysregulation of BP in diseased kidneys ¼¿ïÀÇ´ë Áֱǿí |
|
2004³â Á¦ 2ȸ Á¤±âÇмú´ëȸ |
ÀÏ ½Ã |
2004³â 2¿ù 21ÀÏ(Åä) |
Àå ¼Ò |
°¡Å縯´ëÇб³ ÀǰúÇпø 1002È£½Ç, ¼¿ï |
|
|
Program |
1:30-2:00 |
Molecular Pathogenesis of Nephrogenic Diabetes Insipidus - ¼¿ïÀÇ´ë Á¤ÇØÀÏ |
2:00-2:30 |
Renal Hypophosphatemic Rickets (Osteomalacia) - ¼¿ïÀÇ´ë ÃÖ ¿ë |
2:30-3:00 |
Bartter¡¯s & Gitelman¡¯s syndrome - Àü³²ÀÇ´ë ÃÖ±âö |
3:00-3:40 |
State of the Art Lecture: Management of Hyperkalemia in ESRD - Nippon Medical School, Yasuhiko Iino |
3:40-4:00 |
Coffee break |
4:00-4:30 |
Oxidative Stress and the Kidney - ÇѸ²ÀÇ´ë ±¸ÀÚ·æ |
4:30-5:00 |
Heme Oxygenase in Kidney Disease - °æ»óÀÇ´ë À弼ȣ |
5:00-5:30 |
Osmotic Stress and the Kidney - ¼¿ïÀÇ´ë ³ª±â¿µ |
5:30-6:00 |
Natriuretic Peptides in the Kidney in Hypertension - Àü³²ÀÇ´ë ÀÌÁ¾Àº |
6:30 |
ÆòÀÇ¿øÈ¸; ¸Þ¸®¾îÆ® È£ÅÚ |
|
2003³â Á¦ 1ȸ Á¤±âÇмú´ëȸ |
ÀÏ ½Ã |
2003³â 3³â 8ÀÏ(Åä) |
Àå ¼Ò |
°¡Å縯´ëÇб³ ÀǰúÇпø 1002È£½Ç |
|
|
Program |
|
SESSION I Reviews |
|
³×ÇÁ·ÐÀÇ ÇØºÎÇÐ - °¡Å縯´ë ±è Áø |
|
Renal Aquaporins - µ¿±¹´ë ±ÇÅÂȯ |
|
½Å¼¼°üÀÇ ¿î¹Ýü - ÇѸ²´ë ±è±ÙÈ£ |
|
Urine Acidification Test - °¡Å縯´ë ÀåÀ±½Ä |
|
½ÅÀå¿¡¼ ÀÌ´¢È£¸£¸óÀÇ »ý¸® ¹× º´Å»ý¸® - Àü³²´ë ±è¼ö¿Ï |
|
SESSION II Case Reports |
|
Herbal Nephropathy - ÇѾç´ë ÇÑ»ó¿õ |
|
Gitelman Syndrome - ¿ø±¤´ë ¼ÛÁÖÈï |
|
Hypokalemic Paralysis associated with Sjogren`s syndrome - °í·Á´ë Ç¥ÈñÁ¤ |
|
Gitelman Syndrome - ÀüºÏ´ë ±è ¿ø |
|
|
|
|